Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
← catalyst calendarSponsored by Eledon Pharmaceuticals (industry) · ELDN — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
127actual
Sites
43
Countries
Australia, Brazil, Canada +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-30 | actual | When the study began enrolling |
| Primary completion | 2025-09-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-25 | actual | The whole study's end, after follow-up |
| First posted | 2023-08-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Kidney Transplant Rejection
Interventions
- Drug: AT-1501 — also filed as Tegoprubart
- Drug: Tacrolimus
Primary outcome
what the primary-completion date above is the date OFeGFR at 12 months
measured Assessed from date of transplant through Day 364 (Month 12)
Permalink · ELDN's whole pipeline · Catalyst calendar · Every registered study · What changed